secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fusion Pharmaceuticals Inc. (—)
CIK:        0001805890
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0000950170-24-053948
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fusion Q1 net loss $33.7M; AstraZeneca acquisition on track for Q2 2024
-----------------------------------------------------------------------

- Net loss of $33.7M ($0.40/sh) vs $24.3M ($0.45/sh) in Q1 2023; R&D spend $21.3M.
- Cash and investments $283.1M as of March 31, 2024; expected to fund operations into Q4 2025.
- Definitive agreement to be acquired by AstraZeneca for up to $2.4B ($21/sh cash + $3 CVR); HSR clearance and Canadian Competition Bureau no-action received; expected close Q2 2024.
- Interim data for FPI-2265 in mCRPC presented at AACR 2024; Phase 2 dose optimization trial to start Q2 2024, Phase 3 registrational trial planned for 2025.
- FPI-1434 Phase 1 trial shows encouraging early findings; no DLTs in 25 kBq/kg cohort; stable disease and anti-tumor activity observed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1805890/000095017024053948/0000950170-24-053948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1805890/000095017024053948/fusn-20240507.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-053948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer